STIM VS ABBV Stock Comparison

Performance

STIM
10/100

STIM returned -72.04% in the last 12 months. Based on SPY's performance of -13.39%, its performance is below average giving it a score of 10 of 100.

ABBV
100/100

ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

STIM
90/100

5 analysts offer 12-month price targets for STIM. Together, they have an average target of 8, the most optimistic target put STIM at 8 within 12-months and the most pessimistic has STIM at 8.

ABBV
68/100

20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.

Sentiment

STIM
74/100

STIM had a bullish sentiment score of 74.22% across Twitter and StockTwits over the last 12 months. It had an average of 3.11 posts, 0.22 comments, and 0.44 likes per day.

ABBV
71/100

ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.

Technicals

STIM
64/100

STIM receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

ABBV
11/100

ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

STIM
24/100

STIM has missed earnings 4 times in the last 20 quarters.

ABBV
100/100

ABBV has missed earnings 0 times in the last 20 quarters.

Profit

STIM
10/100

Out of the last 20 quarters, STIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ABBV
80/100

Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

STIM
33/100

STIM has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

ABBV
47/100

ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

STIM

"Dividend" not found for STIM

ABBV
100/100

ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Neuronetics, Inc. Common Stock Summary

Nasdaq / STIM

Healthcare

Medical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

ABBVIE INC. Summary

New York Stock Exchange / ABBV

Healthcare

Drug Manufacturers - General

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Power up your portfolio